Navigation Links
Fragile US vaccine system needs improvement despite dramatic gains in health over past century

A comprehensive system of vaccine development in the U.S. resulted in a reduction of 87 to more than 99 percent in illness from ten vaccine-preventable diseases during the twentieth century. These dramatic successes should not be taken for granted, however, as the vaccine system now faces numerous challenges in manufacturing and development, according to a review article in the May/June issue of Health Affairs.

The U.S. vaccine system is a complex collaboration among government, industry, providers, academia, professional societies and third-party payers that has resulted in record low levels of vaccine-preventable diseases and record high levels of immunizations among children. According to the article, however, problems with vaccine supply, cost and safety threaten to derail the vaccine successes of past decades, and the system faces additional challenges posed by the adult immunization program, the need for adequate research and development and the requirement of biopreparedness.

Walter A. Orenstein, director of the Emory Program for Vaccine Policy and Development and associate director of the Emory Vaccine Center at Emory University was lead author of the article. His research was partly supported by the National Institutes of Health. Co-authors included R. Gordon Douglas, consultant in vaccines, infectious diseases and global health; Lance Rodewald, director of the Immunization Services Division in the National Immunization Program at the U.S. Centers for Disease Control and Prevention (CDC); and Alan Hinman, senior public health scientist, Task Force for Child Survival and Development In addition to the major reductions in illness during the twentieth century from smallpox, diphtheria, measles, mumps, pertussis, polio, rubella, congenital rubella syndrome, tetanus, and H. influenzae, type b (in children less than 5 years old), new vaccines in the past 10 years for varicella (chickenpox), hepatitis A, and pneumococcal disease have led to signific ant reductions in disease in young children, including a drop of 92 percent in mortality from chickenpox in children four years and younger.

Despite its successes, the U.S. vaccine system is fragile and needs significant improvements, the authors report. Since 2000, vaccines against nine of the twelve vaccine-preventable diseases of childhood have been in short supply. As of 2004 only four commercial companies produce vaccines for young children, and vaccines for seven of the preventable diseases of childhood are manufactured by only one company. The rising cost of vaccines, due partly to compliance with regulations and liability concerns, threatens the widespread availability of vaccines for children. The most recent estimates (2000) of the cost to develop a new vaccine range from $110 million to $802 million, and five vaccines recently reviewed by the National Vaccine Advisory Committee took from two to twenty-one years from Phase I clinical trials to licensing.

Safety concerns, such as the problem with the rotavirus vaccine in 1998 as well as unfounded and unproven concerns about other vaccines threaten to lead to decreased vaccine coverage and outbreaks of vaccine-preventable infectious diseases. Adult immunizations, while effective, have not been as effective as childhood vaccines. However, even the most effective ones do not have the wide coverage of childhood vaccines.

"Although immunization can be counted as one of the major successes of medicine, the recent short supplies of childhood vaccines and the recent problems with influenza vaccine are a clear sign of the importance of continuing to improve the system for vaccine development and manufacture," Dr. Orenstein emphasizes. "Manufacturers need to have adequate returns on their investments, healthcare providers need to be fairly reimbursed, resources should be available to monitor vaccine effectiveness and safety, and loopholes need to be closed in the vaccine injury compensation pr ogram. Incentives should be available to encourage the development of new vaccines, from basic research to manufacture."


'"/>

Source:Emory University Health Sciences Center


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research ... Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity ... ... Report, forecasts that the global market is projected to reach $15,737 ... of 13% from 2016 to 2022. Omic technologies ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the ... 2025" report to their offering. Report ... provides a detailed analysis on current and future market trends to identify ... market values as the base numbers Key market trends ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
Breaking Biology Technology: